Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer

Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer

Biliary tract cancer (BTC) is a gastrointestinal malignancy associated with a poor survival rate. Current therapies encompass palliative and chemotherapeutic treatment as well as radiation therapy, which results in a median survival of only one year due to standard therapeutic ineffectiveness or res...

Full description

Bibliographic Details
Main Authors: Dino Bekric, Daniel Neureiter, Celina Ablinger, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Martin Jakab, Johannes Bischof, Ulrich Koller, Tobias Kiesslich, Christian Mayr
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
biliary tract cancer
cholangiocarcinoma
EZH2 inhibitor
epigenetics
tazemetostat
Online Access:https://www.mdpi.com/2072-6694/15/5/1569

Internet

https://www.mdpi.com/2072-6694/15/5/1569

Similar Items